Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

MILWAUKEE, Dec. 14, 2023 /PRNewswire/ -- Ademi LLP is investigating Rain (NASDAQ: RAIN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pathos.

Click here to learn how to join the https://www.ademilaw.com/case/rain-oncology-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Rain stockholders will receive only $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share. The transaction agreement unreasonably limits competing transactions for Rain by imposing a significant penalty if Rain accepts a competing bid. Rain insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Rain's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Rain common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/rain-oncology-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP